Itb-Med
Itb-Med is recorded as a service provider in 3 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 3 of 3 trials · Latest update first
A 12-month, randomized, single-blind, placebo-controlled exposure-response study of TCD601 (siplizumab) in new onset type 1 diabetes patients (STRIDE)
Sponsor Itb-Med AB
- Start (EU)
- Latest update
- Estimated end
A 60 month, single-arm, proof-of-concept study to induce allogeneic tolerance in deceased donor liver transplant recipients using siplizumab, an anti-CD2 antibody in combination with cyclophosphamide and splenectomy.
Sponsor Itb-Med AB
- Start (EU)
- Latest update
- Estimated end
- Not reported
A 12-Month, Randomized, Controlled, Open-Label, Dose Escalation Study Evaluating Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of an Anti-CD2 Monoclonal Antibody, TCD601(siplizumab) Compared to Anti-Thymocyte Globulin (rATG), as Induction Therapy in de novo Renal Transplant Recipients
Sponsor Itb-Med AB
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Itb-Med?
The 2026-10-09 snapshot links Itb-Med to 3 distinct CTIS trials. Recorded services include All tasks of the Sponsor, Investigator recruitment, Medical writing, Quality assurance & auditing, among 7 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Itb-Med?
Therapeutic-area tags are not recorded in this snapshot. Study-phase tags are not recorded. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Itb-Med conducted?
The linked trials record locations in 5 countries, including Sweden, Spain, Austria, Belgium, Italy. These are trial locations, not confirmed office locations or countries where Itb-Med delivered services.
What can this page tell me about Itb-Med's trial experience?
Browse 3 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Itb-Med. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Itb-Med LLC